ScoutQuest16 Nov 2026
Sai Parenterals544742Acquisition deal news

Board approves signing agreement to acquire majority stake in Bion Therapeutics via wholly owned subsidiary

Board of Sai Parenterals Ltd, at its meeting on 16 November 2026, approved signing an agreement, through wholly owned subsidiary SP Analytics Private Limited, to acquire a majority stake in Bion Therapeutics (India) Private Limited.

By ScoutQuest · · 2 min read

Target Turnover
Rs. 28.22 Cr for the half-year ended 30 September 2026
Expected Completion
on or before 30 November 2026
Deal Funding
IPO proceeds earmarked for General Corporate Purposes and debt

What the board approved

Who is being acquired

The target, Bion Therapeutics (India) Private Limited, was incorporated on 5 September 2005 to undertake testing, analysis and examination of pharmaceuticals, medicines, drugs and other materials. The update describes it as a Hyderabad-based branded formulations prescription business operating in the pharma sector.

Size of the target

How it is being funded

The board also approved providing the necessary funding support to SP Analytics Private Limited for completing the proposed acquisition, through utilisation of the proceeds earmarked for General Corporate Purposes (GCP) from the company's IPO proceeds and debt, subject to applicable laws and requisite approvals.

Related party angle

The update states the transaction will be evaluated in accordance with the applicable provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with respect to related party transaction requirements, and that the interest, if any, of the Promoter(s)/Promoter Group in the target entity or the selling shareholders shall be disclosed as applicable. The acquisition is intended to be undertaken on an arm's-length basis, subject to appropriate assessment and valuation, wherever applicable.

Points a retail investor can track

More numbers
  • Bion Therapeutics turnover, half-year ended 30 September 2026Rupees 28.22 Cr
  • Bion Therapeutics total income, 2024-2547.14
  • Bion Therapeutics total income, 2025-2647.29
  • Bion Therapeutics total income, half-year ended 30 September 202628.75
Source: BSE · 16 Nov 2026

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev